NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Neuphoria Therapeutics Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026
$3.31+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $17.90M
- P/E (TTM)
- –
- Dividend yield
- –
Neuphoria Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Market Cap | $99.51K | $164.85M |
| Enterprise Value | -$19.77M | $87.06M |
| PB Ratio | 0.00 | 2.03 |
| P/TBV Ratio | 0.01 | 2.31 |
Income (trailing twelve months)
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$16.45M | -$21.44M |
| Pretax Income | -$13.59M | -$14.45M |
| Net Income | -$13.45M | -$22.46M |
| EBITDA | -$15.79M | -$16.91M |
Returns
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -61.7% | -53.1% |
| Return on Assets (ROA) | -47.0% | -41.0% |
| Return on Invested Capital (ROIC) | -272.9% | -32.0% |
| Return on Capital Employed (ROCE) | -58.9% | -37.8% |
Balance sheet
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $19.87M | $62.42M |
| Net Cash (Debt) | $19.87M | $15.68M |
| Net Cash Per Share | $3.67 | $0.66 |
| Equity (Book Value) | $24.60M | $48.79M |
| Book Value Per Share | $4.55 | $1.36 |
| Tangible Book Value | $16.96M | $23.06M |
| Working Capital | $20.31M | $75.77M |
Financial position
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 27.85 | 3.30 |
| Quick Ratio | 27.33 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$12.35M | -$12.35M |
Efficiency
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.92M | -$703.34K |
| Employee Count | 7 | 74 |
Dividends and yields
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -13518.4% | -22.7% |
| Buyback Yield | -18004.4% | -0.73% |
| Shareholder Yield | -18004.4% | 0.00% |
Shares
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 5,411,330 | 58,179,650 |
| Shares Change (YoY) | 170.9% | 11.1% |
| Shares Change (QoQ) | 0.63% | 0.54% |
| Shares Held by Institutions | 36.8% | 59.4% |
Taxes
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$139.17K | $91.50K |
Scores
| Measure | Neuphoria Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -10.38 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Neuphoria Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.